December 20, 2011 – Boston Scientific reported positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the Ion (Taxus Element) paclitaxel-eluting patinum chromium stent system versus prior-generation paclitaxel-eluting stents.  Results were presented today by PERSEUS clinical program principal investigators Louis Cannon, M.D., of the Cardiac and Vascular Research Center of Northern Michigan in Petoskey, Mich., and Dean Kereiakes, M.D., medical director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

December 20, 2011 — Aware Inc. announced the introduction of two new server-based software products: AccuRad REM Server and WebView Module for AccuRad ImageShare Server. The products leverage advanced features of the company's AccuRad Server infrastructure to address two different applications: radiation exposure monitoring and viewing of radiology and pathology images.

Vendors showcase the latest medical imaging technological advances each year during the annual Radiological Society of North America (RSNA) meeting in Chicago, always held the week following Thanksgiving. After spending a week walking the show floor and meeting with scores of vendors at RSNA 2011, the following are my choices for the most innovative new technologies presented this year.

A New Chapter Opens for Ultrasound Visualization

Each year that I attend Transcatheter Cardiovascular Therapeutics (TCT), I comb the event and its sessions looking for the next big trend or technological innovations in cardiovascular devices. Below are my finds for the most cutting-edge and futuristic technologies at TCT 2011.

Robots in the Cath Lab

December 20, 2011 –– Howie Lindeman was facing the loss of his career and Neim Malo wasn’t supposed to see 2011. They were each treated for heart disease years ago using their own stem cells to repair their damaged heart tissue. Several years following treatment from Regenocyte, both men continue to see improvement in their condition and quality of life.

December 20, 2011 – The U.S. Food and Drug Administration (FDA) completed a safety review of the anti-arrhythmia drug Multaq (dronedarone). It showed an increased risk of serious cardiovascular events, including death, when used by patients in permanent atrial fibrillation (AF).

 

December 19, 2011 – The role of cardiovascular ultrasound in the catheterization laboratory has never been appreciated more than it is today. Transcatheter aortic valve implantation (TAVI) allows a multidisciplinary team of interventionalists and echocardiographers to replace a patient's diseased aortic valve without traditional open-heart surgery, enabling a new and potentially life-saving method of treatment for inoperable patients with severe symptomatic aortic stenosis.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now